Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanarus Medical has announced a partnership with breast care physicians from select centers across the country to increase the awareness and availability of Visica 2, an innovative, non-surgical treatment option for women with benign breast tumors, known as fibroadenomas.
Subscribe to our email newsletter
In partnership with Sanarus, these centers will participate in regional and national efforts to increase patient and primary care physician awareness of the Visica 2 treatment as a minimally invasive, highly safe and effective treatment alternative to surgical excision. These centers will also participate in a patient registry to document the clinical outcomes and patient satisfaction rates following Visica 2 treatment.
Additionally, these centers are dedicated to expanding private health insurance coverage of this important treatment option, making it more widely available to women across the country. Sanarus plans to include as many as 20 centers in this program before the end of 2007.
The original Visica treatment system received FDA market clearance in 2002 and according to the company, has been proven highly safe and effective with more than 1,500 fibroadenomas treated. The Visica 2 treatment system uses liquid nitrogen as the freezing agent, obviating the need for large, high pressure tanks of argon and helium used in the original Visica Treatment System. Early experience has shown excellent physician and patient satisfaction with the new Visica 2 treatment system